HomeONC • TSE
add
Oncolytics Biotech Inc
Previous close
$1.22
Day range
$1.20 - $1.22
Year range
$1.20 - $3.03
Market cap
92.45M CAD
Avg Volume
45.11K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (CAD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.92M | 10.61% |
Net income | -7.26M | 2.49% |
Net profit margin | — | — |
Earnings per share | -0.10 | 13.68% |
EBITDA | -7.89M | -10.55% |
Effective tax rate | -1.33% | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 24.85M | 2.05% |
Total assets | 32.07M | 0.32% |
Total liabilities | 13.76M | 41.44% |
Total equity | 18.31M | — |
Shares outstanding | 76.99M | — |
Price to book | 5.08 | — |
Return on assets | -59.26% | — |
Return on capital | -90.99% | — |
Cash Flow
Net change in cash
| (CAD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -7.26M | 2.49% |
Cash from operations | -6.82M | 19.44% |
Cash from investing | -155.00K | -102.28% |
Cash from financing | 1.98M | -46.51% |
Net change in cash | -4.75M | -388.41% |
Free cash flow | -4.52M | 24.11% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
29
